Clinical Study results show that QuikClot promotes rapid bleeding control and effective hemostasis i

Data from a recent study of Z-Medica’s QuikClot® hemostatic gauze demonstrated QuiKClot® to be a safe and effective way to achieve hemostasis in pediatric patients undergoing adenotonsillectomy. The data will be presented by Dr. Estela Chavez Delgado, PI for the study during the annual meeting of the American Academy of Otolaryngology – Head and Neck Surgery (AAO-HNSF) on Monday, October 5, 2009 between 11:00 a.m. and 11:28 a.m. PT.

Clinical Study results show that QuikClot promotes rapid bleeding control and effective hemostasis in pediatric patients

Data from a recent study of Z-Medica’s QuikClot® hemostatic gauze demonstrated QuiKClot® to be a safe and effective way to achieve hemostasis in pediatric patients undergoing adenotonsillectomy. The data will be presented by Dr. Estela Chavez Delgado, PI for the study during the annual meeting of the American Academy of Otolaryngology – Head and Neck Surgery (AAO-HNSF) on Monday, October 5, 2009 between 11:00 a.m. and 11:28 a.m. PT.

The purpose of the study was to evaluate the safety and efficacy of QuikClot® kaolin-based hemostatic dressings in 123 pediatric patients undergoing adenotonsillectomy.  The study found that the use of the hemostatic gauze resulted in excellent outcomes.  With the application of QuikClot® hemostatic gauze, the average time to bleeding control was 108+/-61 seconds and complete hemostasis was achieved within five minutes in 83 percent of cases (vs. 27% when standard surgical technique was used p‹0.001).  Additionally, a greater proportion of patients treated with QuikClot had slight or absent throat pain 18 hours following surgery and minimal peritonsillectomy inflammation was found in 69.4 percent of patients in the study group.  Children treated with QuikClot were able to start liquid diet significantly sooner than controls and required significantly less pain control medications.

We are pleased that the initial study findings indicate that QuikClot® is safe and effective for use following pediatric adenotonsillectomy,” said Dr. Giacomo Basadonna, chief medical officer, Z-Medica.  “As we identify possible new uses within the hospital environment, our team of medical professionals is developing  QuickClot® hemostatic gauze products best suited for various new external applications.

About Z-Medica

Z-Medica Corporation is a medical device company developing innovative and cost-effective hemostatic agents. The company manufactures and markets its QuikClot® family of products for hemostasis for use by health care professionals, first responders, law enforcement officers and the military. QuikClot products rapidly enhance the body’s natural coagulation process, helping to achieve hemostasis faster. Z-Medica’s QuikClot® Combat Gauze™ product was chosen by the Committee on Tactical Combat Casualty Care (TCCC) as the United States Military’s sole source supplier for first-line hemostatic treatment, based on tests conducted by the Naval Medical Research Center and the U.S. Army Institute for Surgical Research. QuikClot® products are also widely used by first responders, in hospital emergency rooms, interventional cardiology and radiology laboratories and other healthcare environments where bleeding requires fast and effective control. Z-Medica, named one of the Top 100 Technology “Companies to Watch” in 2008 by the Connecticut Technology Council, is a privately-held company based in Wallingford, CT.